EFFICACY OF ORAL VORICONAZOLE VERSUS ORAL ITRACONAZOLE, IN THE TREATMENT OF DERMATOPHYTE INFECTIONS
DOI:
https://doi.org/10.55519/JAMC-02-12891Keywords:
voriconazole, dermatophytes, itraconazole, tinea, resistant, antifungal, tropical, response, efficacy.Abstract
Background: Dermatophyte infections are common in tropical areas with a humid climate. In recent times, it is getting extremely challenging to treat these infections because of resistance that has occurred to the conventional antifungals, which is attributed to changes in the fungal strains. Keeping in view this issue, more advanced drugs have come into being. Voriconazole is a potential such drug with promising results. Methods: A total of 76 patients participated in the study, they were divided into two groups, with 38 participants in each group. Group A was treated with voriconazole and group B was treated with itraconazole, for 2 weeks in patients who achieved a complete response, and 4 weeks for patients who achieved a partial response. Baseline complete blood count, Liver function tests, renal function tests, blood sugar levels, and KOH microscopy was done for every patient, and was repeated after completion of treatment. Clinical response was assessed on the basis of clearance of the lesion and negativity on KOH microscopy. Results: After completion of treatment with voriconazole, 32 (84.2)% of the patients achieved a complete clearance of the lesion, while 6(15.8%) of the participants achieved partial response to the treatment. Among the patients who received oral itraconazole,6 (15.7%) showed a complete response ,16 (42.1%) participants achieved a partial cure, while 16 (42.2%) patients did not show any improvement after the treatment. Conclusion: It is safe to conclude, that voriconazole shows better efficacy and results in treating resistant dermatophyte infections.References
Zorab HK, Amin SQ, Mahmood HJ, Mustafa HH, Abdulrahman NM. Dermatophytosis. One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan. 2023;3:99-106.
AL-Khikani FH. Dermatophytosis a worldwide contiguous fungal infection: Growing challenge and few solutions. Biomedical and Biotechnology Research Journal (BBRJ). 2020 Apr 1;4(2):117-22.
Taghipour S, Abastabar M, Piri F, Aboualigalehdari E, Jabbari MR, Zarrinfar H, Nouripour-Sisakht S, Mohammadi R, Ahmadi B, Ansari S, Katiraee F. Diversity of geophilic dermatophytes species in the soils of Iran; the significant preponderance of Nannizzia fulva. Journal of Fungi. 2021 Apr 28;7(5):345.
Singh S, Chandra U, Anchan VN, Verma P, Tilak R. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. British Journal of Dermatology. 2020 Nov 1;183(5):840-6.
Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin–a prospective, randomized comparative study. Indian journal of pharmacology. 2019 Mar;51(2):116.2(1):1.
Sardana K, Mathachan SR. Super bioavailable itraconazole and its place and relevance in recalcitrant dermatophytosis: Revisiting skin levels of itraconazole and minimum inhibitory concentration data. Indian Dermatology Online Journal. 2020 Jan;1
Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. Journal of Dermatological Treatment. 2020 Oct 2;31(7):749-53.;
Maxfield L, Preuss CV, Bermudez R. Terbinafine.
Kurn H, Wadhwa R. Itraconazole.
Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, Das A, Bisherwal K, Shaw D, Vasani R. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian journal of dermatology, venereology and leprology. 2021 Mar 23;87(2):154-75.
Sharquie KE, Jabbar RI. New multiple therapy of resistant and relapsing dermatophyte infections during epidemic status. Journal of Pakistan Association of Dermatologists. 2022 Aug 27;32(3):464-71.
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, Bromley M, Brüggemann R, Garber G, Cornely OA, Gurr SJ. Tackling the emerging threat of antifungal resistance to human health. Nature reviews microbiology. 2022 Sep;20(9):557-71
Hendrickson JA, Hu C, Aitken SL, Beyda N. Antifungal resistance: a concerning trend for the present and future. Current infectious disease reports. 2019 Dec;21:1-8
Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metabolism Reviews. 2019 Jul 3;51(3):247-65
Khattab F, Elkholy BM, Taha M, Abd‐Elbaset A, Fawzy M. Voriconazole is superior to combined itraconazole/isotretinoin therapy and itraconazole monotherapy in recalcitrant dermatophytosis. Mycoses. 2022 Dec;65(12):1194-201.
https://www.openepi.com/SampleSize/SSCohort.htm
Kelsey et al., Methods in Observational Epidemiology 2nd Edition, Table 12-15
BS C, Poojitha DS. Evaluation of efficacy and safety of oral voriconazole in the management of recalcitrant and recurrent dermatophytosis. Clinical and Experimental Dermatology. 2022 Jan 1;47(1):30-6.
Shahzad MK, Hassan T, Tahir R, Jawaid K, Khan MF, Naveed MA. Efficacy of Oral Voriconazole in the Treatment of Dermatophyte Infections (Tinea Corporis and Cruris). Pakistan Journal of Medical & Health Sciences. 2022 Mar 26;16(02):330-.
Khondker L. Efficacy and safety of voriconazole in the treatment failure cases of Dermatophytosis. Gulf J. Dermatol. Venereol. 2020;27:30.
Panagiotidou D, Kousidou T, Chaidemenos G, Karakatsanis G, Kalogeropoulou A, Teknetzis A, Chatzopoulou E, Michailidis D. A Comparison of Itraconazole and Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris: A Double-Blind Study. Journal of international medical research. 1992 Sep;20(5):392-400.
Ahmed SS, Ahmed SS, Haque MM, Tabassum F. Efficacy and Safety of Oral Voriconazole in Refractory and Recurrent Cases of Dermatophytosis: A Prospective Study in a Tertiary Care Hospital in Bangladesh.
Comparison of Itraconazole and Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris: A Double-Blind Study. Journal of international medical research. 1992 Sep;20(5):392-400.Kafi MA, Akter M, Khan R, Ahmed SS, Hassan.
Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, Van Vliet M, Sonneveld P, van Schaik RH. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Journal of Antimicrobial Chemotherapy. 2007 Nov 1;60(5):1104.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Maira Ali, Najia Ahmed, Seemab Khan, Afshan kiran
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
